🚨🥁ANNOUNCEMENT: Precision medicine & tumor-agnostic drug development take center stage ESMO - Eur. Oncology #ESMO24 ! ‼️👉Honored to be invited to speak at the SPECIAL ESMO & ASCO joint session in Barcelona, Spain on "Tumour-agnostic drug development" at the ESMO congress 2024. 👉Chaired

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial: brnw.ch/21wMdrP #pancsm

📢Hepatopancreaticobiliary-NET abstracts in #ESMO24 ESMO - Eur. Oncology ➡️HCC ✅LBA3 - Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study ✅LBA38 - Iparomlimab and

The first prospective evidence on neoadjuvant RLT for pancreatic NET is finally out on BJS .Great team work from eight Italian centers 🇮🇹 ENETS NANETS NET Cancer Day Neuroendocrine Cancer UK #NotJustNECancer Neuroendocrine Cancer NET CANCER FOUNDATION NETs México NET Research Foundation NETwerk NET- ESPAÑA

Only 2 weeks to submit your abstract for #ukinets conference 2024 - submit here: ukinets.org/uki-nets-2024-…

Impact of Adjuvant Chemotherapy on Resected IPMN-Derived #pancsm should we omit adjuvant chemo in N0, CA19.9 low cases? Prospective data are needed ⁦Journal of Clinical Oncology⁩ ascopubs.org/doi/abs/10.120…

Updated data for atezo + bev vs surveillance in resected or ablated high risk HCC #ESMO24 🔎IMbrave050 👉RFS 33.2 vs 36 mo, HR 0.9 👉OS: HR: 1.26 🧐Benefit not sustained! Disappointing.. 🧐Caveat of (too) early read outs… ESMO - Eur. Oncology #ESMOAmbassadors @ILCA EASL Education

PANDAS PRODIGE 44 BR-PDAC ➡️mFFX vs mFFX + caperads 50.4Gy ➡️No diff in R0 resection rate ➡️No diff in mOS 32.8 vs 30mths ➡️numerically longer locoregional recurrence rate in RT arm but not sig ‼️imp to note in those randomised how many get to adjuvant ~50% #ESMO2024 HPB Dublin

Informative session on CUP #ESMO24 ESMO - Eur. Oncology Natalie Cook 💙 with recent publication of CUPISCO trial leading to changes in ESMO guidelines; benefit of molecularly guided therapies and importance of molecular profiling The Christie NHS Manchester Cancer Research Centre

Points highlighted and controversies in BTC discussed by Profs Lowery & Chan #ESMO2024 ; liquid biopsy may miss FGFR2 fusions, role for transplant/loco regional Rx in CCA, sequencing of FGFR2 inhibitors, rise in early onset BTC-metabolic factors? ESMO - Eur. Oncology

LEAP-012 met primary end-point of PFS; 14.6mo vs 10mo for Pembro/lenva/TACE vs TACE/placebo. Trend for OS benefit. Mature follow up will be needed. If becomes standard, what to choose in first-line metastatic?

Lovely night at the MCRC - The Christie, Manchester #ESMO2024 Academic reception in Barcelona Natalie Cook 💙 Manchester Cancer Research Centre The Christie NHS ESMO - Eur. Oncology

Ready for another great day at #ESMO24! This morning Robin Zon, MD, FACP, FASCO is co-chairing w Andres Cervantes a session at which our CMO Julie Gralow is speaking, “Novel Pathways for Development of Precision Therapeutics in Molecular Oncology” w/ Dr. Gralow focusing on “regulatory sandboxes.”

Timely/topical ASCO @ESMO session #ESMO24 on potential pt benefit of organoids, challenges of tumour agnostic/accelerated approvals, cautious optimism around AI & accessibility issues; LMIC issues probably worse Herbert Loong, MBBS, FASCO Vivek Subbiah, MD Robin Zon, MD, FACP, FASCO Julie Gralow

Dilemmas in HPB cancers discussed ESMO - Eur. Oncology #ESMO2024 ; 5 yr survival in HCC 50-70%; need for neo-adjuvant/adjuvant success. What to do in special subgroups in HCC & BTC re: immunotherapy, & need for immuno bio markers in both groups Lorenza Rimassa Arndt Vogel

Updated discussion on Checkmate 9DW & HIMALAYA in 1L advanced HCC ESMO - Eur. Oncology #ESMO2024; why TKI arm does better earlier in Checkmate & improving OS for TKIs over time; pt selection? Further treatment options? More options for pts Lorenza Rimassa ILCA

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors | New England Journal of Medicine nejm.org/doi/full/10.10… Directly from ESMO - Eur. Oncology to NEJM 🙌🏼🙌🏼

📢 #ESMO24 concomitant paper: First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration. #ESMO24 Hans Prenen tinyurl.com/23btbhxd

I'm excited to see this early data at #ESMO24 on AMG 193 for my patients with pancreas, biliary & oesophageal cancer 👏👏 MTAP deletion is a new target for hard to treat cancers annalsofoncology.org/article/S0923-… #Presidential ESMO - Eur. Oncology